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Summary 
Nitric oxide (NO),  a toxic radical gas produced during the metabolism of I.-arginine by NO 
synthase (NOS), has been implicated as a mediator of immune and inflammatory responses. A 
single injection of streptococcal cell wall fragments (SCW) induces the accumulation of inflammatory 
cells within the synovial tissue and a cell-mediated immune response that leads to destructive 
lesions. We show here that NO production is elevated in the inflamed joints of SCW-treated 
rats.  Administration of NG-monomethyl-t-arginine, an inhibitor of NOS, profoundly reduced 
the synovial inflammation and tissue damage as measured by an articular index and reflected 
in  the  histopathology.  These  studies implicate the  NO  pathway  in the  pathogenesis  of an 
inflammatory arthritis and demonstrate the ability of a NOS inhibitor to modulate the disease. 
N 
'itric oxide (NO) participates in intercellular signaling 
when produced in small amounts by constitutive NO 
synthase (cNOS) in neurons and endothelial cells (1, 2). Im- 
munologic and inflammatory stimuli, however, induce an iso- 
form of NOS (inducible NOS [iNOS]) that can produce much 
larger amounts of NO over longer periods (1). In the latter 
circumstances, NO can exert cytostatic or cytotoxic effects 
against microbes, tumor cells, macrophages, and lymphocytes, 
as well as fl cells in the pancreas (1). At the same time, NO 
can suppress the proliferation oft  cells (3-5) and the emigra- 
tion  of neutrophils  (6).  Thus,  while diseases such as  ex- 
perimental acute encephalomyelitis (7), rabies (8), and graft- 
vs.-host disease (9) are accompanied by induction of iNOS 
and/or production of NO, it is diflficult to predict whether 
sustained generation of NO is more likdy to exacerbate chronic 
inflammation or alleviate it. 
Here we present the first evidence that inhibition ofiNOS 
can markedly suppress tissue destruction resulting from chronic 
inflammation. Susceptible rats, exposed to streptococcal cell 
wall fragments (SCW), develop an acute inflammation of the 
joints, followed by a chronic, erosive arthritis (10).  This bi- 
modal pattern of arthritis occurs coinddently with the depo- 
sition and persistence of SCW  antigens in the synovium. 
Whereas the early phase of the response is neutrophil driven, 
the chronic phase has been identified as a T cell- and monocyte- 
mediated immune response and is characterized by infiltra- 
tion of mononudear cells with release of inflammatory medi- 
ators, hyperplasia of the synovium, and erosive destruction 
of the subchondral and periarticular bone and cartilage (11, 
12).  The development of arthritis was accompanied by in- 
duction of iNOS and production of NO both in synovial 
tissue and blood mononuclear cells. Administration of an in- 
hibitor of NOS, NG-monomethyl-t-arginine (NMMA) (13), 
greatly reduced the accumulation of inflammatory leukocytes 
and erosion of the joint. NMMA was effective even when 
its administration was dehyed until after the onset of arthritis. 
Materials  and Methods 
Arthritis Induction.  Arthritis was induced in pathogen-free LEW 
female rats (,,~100 g) (Harlan Sprague Dawley, Indianapolis, IN) 
by intraperitoneal  injection of peptidoglycan-polysaccharide frag- 
ments (20/~g rhamnose/g body mass) derived from group A strep- 
tococcal call walls (11, 12). Each of the four distal joints was scored 
on a scale of 0-4 for severity of arthritis on the basis of swelling, 
erythema, and distortion (11). The individual joint scores were 
summed to determine the articular index (AI), with a possible max- 
imum score of 16. The indices for a group of animals were aver- 
aged and reported as the mean AI -+ SEM. Statistical significance 
was determined using the unpaired, two-tailed t test. NMMA (Cal- 
biochem Corp., San Diego, CA) was injected intravenously daily 
for specified intervals up to 26 d at a dosage of 30 mg/kg body 
weight. The NMMA stock solution was prepared in PBS (100 
mg/ml) and contained g12 pg endotoxin/ml as determined by the 
limulus assay. 
Synovial Tissue Culture  Synodal tissues were excised from con- 
trol and arthritic rats, finely minced, and equivalent amounts based 
on wet weights were cultured in eight-well slide chambers (Nunc, 
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burg, MD) containing gentamicin sulfate (50/~g/ml), 2 mM gluta- 
mine, 100/~M t-arginine, and supplemented with [guanido-14C]t - 
arginine (50 nCi/well;  DuPont Co., Wilmington, DE). Labeled 
urea (arginase pathway) and citrulline (NO pathway) in the super- 
natants were separated by HPLC using an automated amino acid 
analyzer (Dionex, Sunnyvale, CA). Results are reported as the frac- 
tion (%) of total radioactivity found in these compounds at the 
end of culture. The nitrite content of the supernatants was assayed 
with  Griess  reagent  (14).  Samples  were tested in  triplicate and 
reported as the mean concentration  _+  SEM. 
CellIsolation  and Culture,  PBMC were isolated from heparinized 
blood of control and SCW-injected animals by density gradient cen- 
trifugation through Ficoll (Histopaque 1083; Sigma Chemical Co., 
St. Louis,  MO).  Cells  were suspended  in arginine-supplemented 
DME (phenol red-free; Mediatech, Inc., Washington, DC) in 24- 
well plates (Costar Corp., Cambridge, MA) and cultured for 24 h 
in the presence  or absence  of SCW  and NMMA. 
RNA Isolation and Northern Blot Analyses.  Total cellular RNA 
was extracted from cells or homogenized tissue using the guani- 
dine thiocyanate/phenol/chloroform  procedure (15). RNA was sepa- 
rated on 1% agarose gels containing 1.2 M formaldehyde and trans- 
ferred to nitrocellulose  (BA-S; Schleicher and Schuell, Keene, NH). 
The blots were probed with a radiolabeled 645-bp HindlII/BamHI 
fragment of the iNOSL3, a derivative  of the macrophage NOS 
clone (16). The blots were exposed to phosphor screens and ana- 
lyzed by a Phosphorimager (Molecular Dynamics, Sunnyvale, CA) 
using  ImageQuant  software.  The blots were then stripped and 
screened  with a probe encoding glyceraldehyde-3-phosphate de- 
hydrogenase (GAPDH), a constitutively expressed  housekeeping 
gene (17). 
Histo~thology.  Joint tissues from control and arthritic rats were 
excised  and fixed in  10%  buffered formalin, decalcified in  10% 
EDTA, embedded in paraffin,  sectioned, and stained  with hema- 
toxylin and eosin. 
Results and Discussion 
Production of  NO in SCW-induced Arthritis.  To test whether 
NO was associated with the evolution of chronic inflamma- 
tion,  susceptible rats were injected with SCW to induce an 
acute inflammation of the joints, followed by a chronic, ero- 
sive arthritis (11). Synovial tissue excised from inflamed joints 
and placed in culture secreted NO, as measured by formation 
of nitrite (NO2-),  a stable decomposition product of NO, 
during  the acute and  the chronic phases  of disease  (Fig.  1 
A), in contrast to control synovium. Moreover, the inflamed 
Figure  1.  NO production in synovial  tissues is as- 
sociated with arthritis development.  Animals received 
a single  intraperitoneal  injection  of  an arthropathlc  dose 
of SCW on day 0. Synovial  tissues were excised  from 
joints of nine control rats (AI  =  0), two rats with 
acute inflammation  (day  3, AI ~3/joint), and two rats 
with chronic  inflammation  (day 17, AI ~3/joint), and 
samples were pooled for each condition. Equivalent 
amounts of tissue based on wet weights (27 mg/0.2 
ml) were cultured in duplicate  for 24 h in the presence 
of [guanido-14C]t-arginine. (/1) Quantitation of ni- 
trite by the Griess reaction  and [14C]urea  and [14C]cit- 
rutline by HPLC analysis  of  synovial  tissue culture su- 
pernatants. (B) Northern blot hybridization  of  synovial 
tissue RNA from freshly  isolated  control and inflamed 
joints of  representative  animals with cDNA probes  en- 
coding macrophage iNOS and GAPDH. 
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1 B). 
Culture of the synovial tissue in [guanido-14C]I.-arginine 
revealed metabolism by both arginase and NOS (Fig.  1 A). 
Greater than 14% of the arginine metabolized in the inflamed 
synovial tissues, but not in the control tissue (~<1%), passed 
through the NO pathway, as revealed by accumulation of 
[14C]citrulline, providing evidence for inducible NO during 
both acute and chronic inflammation. Arginase accounted 
for a significant proportion of the arginine use as monitored 
by [14C]urea levels. Arginase, produced by macrophages and 
reportedly high at sites of inflammation (18), could diminish 
arginine in the synovial fluids. Under conditions of limiting 
r-arginine concentrations, brain NOS  has been shown to 
generate hydrogen peroxide and superoxide (19, 20), mole- 
cules that contribute to joint pathology in SCW-injected rats 
(12). It is possible  that synovial iNOS uses both oxidative 
pathways in SCW-induced arthritis. 
Systemic Effects of SCW Exposure on NO Production.  PBMC 
isolated from SCW-injected arthritic animals released more 
nitrite than control PBMC (48 vs. 7 nmol nitrite/106 ceils; 
p ~< 0.004)  and, after exogenous addition of SCW in vitro, 
these levels were augmented in both populations (Fig.  2). 
Furthermore, PMN from arthritic animals secreted increased 
nitrite (data not shown). The specific NOS inhibitor NMMA 
blocked NO  generation in  the PBMC  cultures  (Fig.  2). 
Significant suppression was evident at 10 #M NMMA, with 
return to basal NO levels at  100-500 #M. 
To establish whether the SCW could directly induce the 
NO pathway in phagocytic cells, resident peritoneal cells were 
isolated from control animals and exposed to SCW in vitro. 
SCW  induced substantial  NO  synthesis (>120  nmol ni- 
trite/106  cells)  and  high levels of [14C]citrulline  (>25%) 
with little arginase activity. Thus, macrophages and neutro- 
phils, as well as chondrocytes and fibroblasts, which have been 
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Figure  2.  Inhibition of NO synthesis by NMMA. PBMC were iso- 
lated from control and SCW-injected  rats (4 wk postinjection)  and cul- 
tured for 24 h in the presence of SCW (3 #g/ml) and NMMA (0--500 
#M). Nitrite content of the supernatants  was determined and normalized 
to cell concentration.  Data are from a representative experiment  in which 
the individual  means  _+  SEM were determined from duplicate  cultures 
assayed in triplicate. 
shown to express iNOS and/or release NO in response to 
cytokines (1, 21), may contribute to the elevated synovial NO 
levels in SCW-arthritic rats. 
Suppression of Acute and Chronic Arthritis by NMMA, an In- 
hibitor of NOS.  To determine whether the elevated NO levels 
were contributing to tissue pathology, female LEW rats were 
treated with NMMA after a single arthropathic dose of SCW. 
Control rats receiving only SCW developed typical acute and 
chronic arthritis (11, 12) (Fig. 3 A and B). Daily intravenous 
injections of NMMA at 30 mg/kg body weight beginning 
at day 0 resulted in a marked suppression of the cellular infiltrate 
(Fig. 3 C) as reflected by the AI and compared with the un- 
treated arthritic animals (Fig. 3 A). While acute inflamma- 
tion was suppressed clinically (30% on day 3; p ~< 0.0001), 
NMMA did not significantly inhibit acute leukocyte recruit- 
ment (not shown). However,  NMMA virtually eliminated 
the  joint swelling and distortion and greatly reduced the cel- 
lular infiltration during the T  cell macrophage-dependent 
chronic phase of disease (on day 22, AI  =  1.0 _+ 0.8 vs. 9.1 
_+  0.7 for SCW only; p ~< 0.0002).  Moreover,  the AI was 
also reduced significantly (80% on day 22, AI =  4.5 +  1.5; 
p ~< 0.0001) in SCW-injected rats receiving NMMA begin- 
ning on day 12 as the acute response subsided and the chronic 
arthritic phase commenced. Rats receiving NMMA during 
the acute response only (days 0-4) also displayed reduced AI 
during the chronic phase, although the suppression was modest 
and variable (data not shown). NMMA did not appear toxic 
to the animals  even after 26 d of treatment. 
The systemic effects of SCW exposure were demonstrated 
by the induction of NO in circulating mononuclear cells (Figs. 
2 and 4). However, constitutive nitrite production by PBMC 
obtained from NMMA-treated arthritic rats (days 0-26) was 
reduced 70% (p ~ 0.001) compared with arthritic rats. Treat- 
ment with NMMA during the chronic disease only (days 
12-26)  achieved  similar suppression of nitrite production 
(70%; p ~< 0.0005), whereas limiting treatment to the acute 
phase (days 0-4) resulted in a smaller reduction in PBMC 
nitrite levels when evaluated on day 26. 
By Northern analysis, PBMC of SCW-injected rats (days 
3  and 21  postinjection) revealed increased  levels of iNOS 
mKNA (,04.3 kb) compared with control rats (Fig. 4). As 
predicted, NMMA treatment of SCW-injected rats,  while 
reversing the arthritis and inhibiting nitrite production, did 
not decrease levels of iNOS mR-NA (<15% change at day 
21). NMMA treatment alone did not influence iNOS mKNA 
expression. 
We conclude that NO production is necessary for the im- 
munologically mediated  joint destruction induced by SCW. 
The mechanisms by which NO promotes tissue damage in 
this setting have not been established.  Direct effects might 
include toxicity, altered metabolism of synoviocytes and chon- 
drocytes (21), increased permeability of the synovial microvas- 
culature (22), or augmented reactive oxygen intermediate levels 
(19, 20). However, indirect effects, such as inhibition of sup- 
pressor T  cells or antiproteases,  might also play a role. 
Blockade of the NO pathway has been suggested as a treat- 
ment for TNF-induced hypotension (23),  toxic shock syn- 
drome (24),  and diabetes  (25).  The present data appear  to 
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Figure  3.  Suppression  of SCW-induced arthritis by systemic administration of NMMA. Animals received an arthritogenic dose of SCW at day 
0, and NMMA was injected intravenously daily for 26 d beginning on day 0 at a dosage of 30 mg/kg body weight. Some rats received NMMA on 
days 0-4 (data not shown); others received NMMA on days 12-26.  (A) AI scores were determined at indicated intervals and data represents  the mean 
_+  SEM. All control animals (PBS, NMMA alone)  had mean joint scores of zero throughout the experiment. Joints were excised and processed for 
histopathology on day 26. (B) Cellular infiltrate in the synovium of a SCW-injected animal that had evidence of bone erosion and cartilage degradation. 
(C) After NMMA therapy (days 0-26), a reduction in the cellularity  of the synovium during the chronic phase was evident (original magnification, x40). 
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the NO pathway in destructive arthritic lesions. NMMA re- 
duced the inflammation and joint erosion even when the treat- 
ment was ddayed until after the initiation of the chronic ar- 
thritic response.  NMMA is not selective for the different 
isoforms of  NOS. Interference with neuronal and endothelial 
cNOS could affect cell-cell communication, vascular tone, 
and neurotransmission, although the rats treated with NMMA 
did not display any obvious detrimental effects, consistent 
with other studies (26). As the incidence of rheumatoid ar- 
thritis is approaching 1% worldwide (27), new therapies are 
needed. Recent identification  of nitrite in synovial fluid of 
arthritic patients (28, and McCartney-Francis et al., unpub- 
lished observations) further suggests that inhibitors selective 
for iNOS may prove useful in the long-term treatment of 
arthritides  and perhaps  other inflammatory diseases. 
Figure 4.  Differential  effects  of  NMMA treatment on NO production 
and iNOS gene expression. Total RNA isolated from PBMC on days 3 
and 21 post-SCW injection was analyzed  by Northern hybridization  with 
the iNOS and GAPDH probes. After normalization, little or no decrease 
in the NOS/GAPDH ratios was observed  in the SCW + NMMA samples 
as compared with SCW alone. Nitrite levels  were determined in 24-h cul- 
ture supernatants of PBMC (2  x  106/ml)  isolated on day 26 post-SCW 
injection. 
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